News
Health Canada approves Nypozi biosimilar to Neupogen to treat neutropenia.-Tanvex BioPharma, Inc.
Nypozi (TX01), a proposed biosimilar to the reference product – Amgen’s Neupogen -- is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever. According to data from IQVIA, filgrastim product sales were close to $100 million (CAD) in the Canada for the 12 months ended June, 2021.
Condition: Neutropenia
Type: drug